AIM: To investigate the protective effects of gastric pentadecapeptide BPC 157 on acute and chronic gastric ulcers in rats and to compare the results in therapy of human gastric ulcers by different administration methods. METHODS: Gastric pentadecapeptide BPC 157 was administered (initial single or continuous administration) into rats either intragastrically or intramuscularly before (induced acute gastric ulcer) or after (induced chronic gastric ulcer) the applications of inducing agents, and each animal was sacrificed to observe the protective effects of BPC 157 on gastric ulcers. RESULTS: Both intramuscular (im) and intragastric (ig) administration of BPC 157 could apparently reduce the ulcer area and accelerate the healing of induced ulcer in different models and the effect of im administered BPC 157 was better than that of ig. The rats treated with higher dosages (400 ng/kg, 800 ng/kg) of BPC 157 (im and ig) showed significantly less lesion (P<0.01 vs excipient or saline control), the inhibition ratio of ulcer formation varied between 45.7% and 65.6%, from all measurements except 400 ng/kg BPC 157 in pylorus ligation induced model (P<0.05), in which the inhibition rate was 54.2%. When im administered (800 ng/kg BPC 157) in three models, the inhibition ratio of ulcer formation was 65.5%, 65.6% and 59.9%, respectively, which was better than that of famotidine (its inhibition rate was 60.8%, 57.2% and 34.3%, respectively). Continuous application of BPC 157 (in chronic acetate induced gastric ulcer) could accelerate rebuilding of glandular epithelium and formation of granulation tissue (P<0.05 at 200 ng/kg and P<0.01 at 400 ng/kg and 800 ng/kg vs excipient or saline control). CONCLUSION: Both im and ig administered gastric pentadecapeptide BPC 157 can apparently ameliorate acute gastric ulcer in rats and antagonize the protracted effect of acetate challenge on chronic ulcer. The effect of im administration of BPC 157 is better than that of ig, and the effective dosage of the former is lower than that of the latter.
AIM: To investigate the protective effects of gastric pentadecapeptide BPC 157 on acute and chronic gastric ulcers in rats and to compare the results in therapy of humangastric ulcers by different administration methods. METHODS: Gastric pentadecapeptide BPC 157 was administered (initial single or continuous administration) into rats either intragastrically or intramuscularly before (induced acute gastric ulcer) or after (induced chronic gastric ulcer) the applications of inducing agents, and each animal was sacrificed to observe the protective effects of BPC 157 on gastric ulcers. RESULTS: Both intramuscular (im) and intragastric (ig) administration of BPC 157 could apparently reduce the ulcer area and accelerate the healing of induced ulcer in different models and the effect of im administered BPC 157 was better than that of ig. The rats treated with higher dosages (400 ng/kg, 800 ng/kg) of BPC 157 (im and ig) showed significantly less lesion (P<0.01 vs excipient or saline control), the inhibition ratio of ulcer formation varied between 45.7% and 65.6%, from all measurements except 400 ng/kg BPC 157 in pylorus ligation induced model (P<0.05), in which the inhibition rate was 54.2%. When im administered (800 ng/kg BPC 157) in three models, the inhibition ratio of ulcer formation was 65.5%, 65.6% and 59.9%, respectively, which was better than that of famotidine (its inhibition rate was 60.8%, 57.2% and 34.3%, respectively). Continuous application of BPC 157 (in chronic acetate induced gastric ulcer) could accelerate rebuilding of glandular epithelium and formation of granulation tissue (P<0.05 at 200 ng/kg and P<0.01 at 400 ng/kg and 800 ng/kg vs excipient or saline control). CONCLUSION: Both im and ig administered gastric pentadecapeptide BPC 157 can apparently ameliorate acute gastric ulcer in rats and antagonize the protracted effect of acetate challenge on chronic ulcer. The effect of im administration of BPC 157 is better than that of ig, and the effective dosage of the former is lower than that of the latter.
Authors: P Sikiric; M Petek; R Rucman; S Seiwerth; Z Grabarević; I Rotkvić; V Jagić; B Turković; B Mildner; M Duvnjak Journal: Acta Physiol Hung Date: 1992
Authors: P Sikiric; S Seiwerth; Z Grabarevic; I Balen; G Aralica; M Gjurasin; L Komericki; D Perovic; T Ziger; T Anic; I Prkacin; J Separovic; D Stancic-Rokotov; M Lovric-Bencic; D Mikus; M Staresinic; J Aralica; N DiBiaggio; Z Simec; B Turkovic; I Rotkvic; S Mise; R Rucman; M Petek; B Sebecic; Z Ivasovic; A Boban-Blagaic; I Sjekavica Journal: J Physiol Paris Date: 2001 Jan-Dec
Authors: I Prkacin; J Separovic; G Aralicia; D Perovic; M Gjurasin; M Lovric-Bencic; D Stancic-Rokotov; M Staresinic; T Anic; D Mikus; P Sikiric; S Seiwerth; S Mise; I Rotkvic; V Jagic; R Rucman; M Petek; B Turkovic; A Marovic; B Sebecic; A Boban-Blagaic; N Kokic Journal: J Physiol Paris Date: 2001 Jan-Dec
Authors: P Sikiric; S Seiwerth; G Aralica; D Perovic; M Staresinic; T Anic; M Gjurasin; I Prkacin; J Separovic; D Stancic-Rokotov; M Lovric-Bencic; D Mikus; B Turkovic; I Rotkvic; S Mise; R Rucman; M Petek; T Ziger; B Sebecic; Z Ivasovic; V Jagic; L Komericki; I Balen; A Boban-Blagaic; I Sjekavica Journal: J Physiol Paris Date: 2001 Jan-Dec
Authors: P Sikirić; M Petek; R Rucman; S Seiwerth; Z Grabarević; I Rotkvić; B Turković; V Jagić; B Mildner; M Duvnjak Journal: J Physiol Paris Date: 1993
Authors: P Sikiric; S Seiwerth; Z Grabarevic; M Petek; R Rucman; B Turkovic; I Rotkvic; V Jagic; M Duvnjak; S Mise Journal: Life Sci Date: 1994 Impact factor: 5.037
Authors: N Jelovac; P Sikiric; R Rucman; M Petek; A Marovic; D Perovic; S Seiwerth; S Mise; B Turkovic; G Dodig; P Miklic; G Buljat; I Prkacin Journal: Eur J Pharmacol Date: 1999-08-20 Impact factor: 4.432
Authors: P Sikiric; J Separovic; G Buljat; T Anic; D Stancic-Rokotov; D Mikus; A Marovic; I Prkacin; B Duplancic; I Zoricic; G Aralica; M Lovric-Bencic; T Ziger; D Perovic; I Rotkvic; S Mise; M Hanzevacki; V Hahn; S Seiwerth; B Turkovic; Z Grabarevic; M Petek; R Rucman Journal: J Physiol Paris Date: 2000 Mar-Apr
Authors: P Sikiric; J Separovic; G Buljat; T Anic; D Stancic-Rokotov; D Mikus; B Duplancic; A Marovic; I Zoricic; I Prkacin; M Lovric-Bencic; G Aralica; T Ziger; D Perovic; N Jelovac; G Dodig; I Rotkvic; S Mise; S Seiwerth; B Turkovic; Z Grabarevic; M Petek; R Rucman Journal: J Physiol Paris Date: 2000 Mar-Apr
Authors: P Sikirić; S Seiwerth; S Desković; Z Grabarević; A Marović; R Rucman; M Petek; P Konjevoda; S Jadrijević; T Sosa; D Perović; G Aralica; B Turković Journal: Eur J Pharmacol Date: 1999-01-01 Impact factor: 4.432
Authors: Predrag Sikiric; Ki-Baik Hahm; Alenka Boban Blagaic; Ante Tvrdeic; Katarina Horvat Pavlov; Andrea Petrovic; Antonio Kokot; Slaven Gojkovic; Ivan Krezic; Domagoj Drmic; Rudolf Rucman; Sven Seiwerth Journal: Gut Liver Date: 2020-03-15 Impact factor: 4.519
Authors: Predrag Sikiric; Anita Skrtic; Slaven Gojkovic; Ivan Krezic; Helena Zizek; Eva Lovric; Suncana Sikiric; Mario Knezevic; Sanja Strbe; Marija Milavic; Antonio Kokot; Alenka Boban Blagaic; Sven Seiwerth Journal: World J Gastroenterol Date: 2022-01-07 Impact factor: 5.742
Authors: Sven Seiwerth; Marija Milavic; Jaksa Vukojevic; Slaven Gojkovic; Ivan Krezic; Lovorka Batelja Vuletic; Katarina Horvat Pavlov; Andrea Petrovic; Suncana Sikiric; Hrvoje Vranes; Andreja Prtoric; Helena Zizek; Tajana Durasin; Ivan Dobric; Mario Staresinic; Sanja Strbe; Mario Knezevic; Marija Sola; Antonio Kokot; Marko Sever; Eva Lovric; Anita Skrtic; Alenka Boban Blagaic; Predrag Sikiric Journal: Front Pharmacol Date: 2021-06-29 Impact factor: 5.810